Medical Health Cluster


7 días en 7 noticias, 1 cifra y 1 frase

  Lo más destacado Aprueba la FDA de Estados Unidos primer fármaco para la prevención de alergias accidentales a alimentos La Administración de Alimentos y Medicamentos (FDA) de Estados Unidos aprobó el anticuerpo monoclonal omalizumab en adultos y niños mayores de un año para reducir las reacciones alérgicas graves mediadas por inmunoglobulina […]

Read More

Paxlovid Reduces Risk of COVID Death by 79% in Older Adults: Study

The antiviral drug Paxlovid appears to reduce the risk of dying from COVID-19 by 79% and decrease hospitalizations by 73% in at-risk patients who are ages 65 and older, according to a new study published in The New England Journal of Medicine. The pill, which is a combination of the drugs nirmatrelvir and ritonavir, […]

Read More

Fluvoxamine for Treating Patients with COVID-19

Fluvoxamine — a selective serotonin reuptake inhibitor prescribed for various mental health disorders — has been proposed as a treatment for COVID-19, in part because of its putative anti-inflammatory effect. Observational data and a small randomized trial suggested benefit. Now, this drug has been tested in a placebo-controlled, adaptive platform […]

Read More